Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Chao LiLowell HartTaofeek K OwonikokoRaid AljumailyCaio Max Rocha LimaPaul R ConklingRoy Timothy WebbRobert M JotteSteven SchusterWilliam J EdenfieldDeborah A SmithMark SalePatrick J RobertsRajesh K MalikJessica A SorrentinoPublished in: Cancer chemotherapy and pharmacology (2021)
NCT02243150; NCT02499770; NCT02514447.